On July 5, 2017, BeiGene, Ltd. and Celgene Logistics Sàrl, now a wholly owned subsidiary of Bristol Myers Squibb Company entered into a License and Supply Agreement (the "Agreement") pursuant to which the Company was granted the exclusive right to distribute and promote BMS-Celgene's approved cancer therapies, ABRAXANE®, REVLIMID®, and VIDAZA®, in China, excluding Hong Kong, Macau and Taiwan (the "Territory"). As previously disclosed, the Company is currently engaged in arbitration proceedings at the International Chamber of Commerce ("ICC") against BMS-Celgene asserting that BMS-Celgene breached and continues to breach the terms and conditions of the Agreement and a related quality agreement on the grounds, among other things, that BMS-Celgene has failed to ensure the continuity and adequacy of its supply of ABRAXANE® to the Company in accordance with good manufacturing practices ("GMP"). In the arbitration proceeding, the Company is seeking (i) a declaration that BMS-Celgene was and is in breach of the Agreement, (ii) a declaration that BMS-Celgene acted with gross negligence and/or willful misconduct, (iii) an award of damages, and (iv) such other relief as the arbitrators deem appropriate. On October 6, 2021, BMS-Celgene delivered a notice to the Company purporting to terminate the Agreement with respect to ABRAXANE® and providing 180-days' notice that it was withdrawing ABRAXANE® from the range of products for sale or distribution in the Territory pursuant to Section 2.6 of the Agreement.